Top

Published in:

01-11-2004 | Original Article

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell–based cancer vaccination

Authors: Joanna Galea-Lauri, James W. Wells, David Darling, Phillip Harrison, Farzin Farzaneh

Published in: Cancer Immunology, Immunotherapy | Issue 11/2004

Abstract

Dendritic cells (DCs) primed with tumor antigens (Ags) can stimulate tumor rejection. This study was aimed at evaluating the polarization of T-cell responses using various DC Ag-priming strategies for vaccination purposes. DCs cocultured with irradiated “apoptotic” tumor cells, DC-tumor fusions, and DCs pulsed with freeze-thaw tumor lysate Ags served as Ag-primed DCs, with EG7 tumor cells (class II negative) expressing OVA as the model Ag. DCs loaded with class I– and class II–restricted OVA synthetic peptides served as controls. Primed DCs were assessed by the in vitro activation of B3Z OVA-specific CD8 T cells and the proliferation of OVA-specific CD8 and CD4 T cells from OT-I and OT-II TCR transgenic mice, respectively. In vivo responses were measured by tumor regression following treatment with Ag-primed DCs and by CTL assays. Quantification of IL-2, IL-4, IL-5, IFN-γ, and TNF-α by cytometric bead array (CBA) assay determined the polarization of TH1/TH2 responses, whereas H-2 K^b /SIINFEKL tetramers monitored the expansion of OVA-specific T cells. DC-EG7 hybrids stimulated both efficient class I and class II OVA responses, showing that DC-tumor hybrids are also capable of class II cross-presentation. The hybrids also induced the most potent CTLs, offered the highest protection against established EG7 tumors and also induced the highest stimulation of IFN-γ and TNF-α production. DCs cocultured with irradiated EG7 were also effective at inducing OVA-specific responses, however with slightly reduced potency to those evoked by the hybrids. DCs loaded with lysates Ags were much less efficient at stimulating any of the OVA-specific T-cell responses, showed very little antitumor protection, and stimulated a weak TH1 response, overbalanced by an IL-5 TH2 response. The strategy of Ag-loading clearly influences the ability of DCs to polarize T cells for a TH1/TH2 response and thus determines the outcome of the elicited immune response, during various vaccination protocols.

Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T (2001) Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 24:106

Amoscato AA, Prenovitz DA, Lotze MT (1998) Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 161:4023PubMed

Bakker ABH, Marland G, Deboer AJ, Huijbens RJF, Danen EHJ, Adema GJ, Figdor CG (1995) Generation of antimelanoma cytotoxic t-lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in-vitro. Cancer Res 55:5330PubMed

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulandran B, Palucka K (2000) Immunobiology of Dendritic Cells. Annu Rev Immunol 18:767PubMed

Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski K, Bhardwaj N, Piniero L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451PubMed

Barnden MJ, Allison J, Heath WR, Carbone FR (1998) Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 76:34PubMed

Bennett SRM, Carbone FR, Karamalis F, Miller JF, Heath WR (1997) Induction of a CD8(+) cytotoxic T lymphocyte response by cross-priming requires cognate CD4(+) T cell help. J Exp Med 186:65PubMed

Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini J, Banchereaux J, Palucka AK (2000) Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192:1535CrossRefPubMed

Berlyn KA, Schultes B, Leveugle B, Noujaim AA, Alexander RB, Mann DL (2001) Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol 101:276PubMed

10.

Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465PubMed

11.

Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309PubMed

12.

Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102PubMed

13.

Burdin N, Moingeon P (2001) Cancer vaccines based on dendritic cells loaded with tumor-associated antigens. Cell Biol Toxicol 17:67CrossRefPubMed

14.

Chevallier P, Spisek R, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL. Meflah K, Gregoire M (2001) Induction of leukemia-specific autologous CTLs by leukemia derived dendritic cells or dendritic cells pulsed with autologous killed leukemic blasts: potential implications for immunotherapy of acute myeloid leukemia. Blood 98:3013

15.

Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233PubMed

16.

Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, Donahoe SM, Dunbar PR, Cerundolo V, Nixon DF, Bhardwaj N (1999) Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104:173PubMed

17.

Dillon SR, Jameson SC, Fink PJ (1994) V-beta-5(+) T-cell receptors skew toward ova+H-2 k(b) recognition. J Immunol 152:1790PubMed

18.

Eggert AAO, Schreurs MWJ, Boerman OC, Oyen WJC, de Boer AJ, Punt CJ, Figdor CG, Adema GJ (1999) Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59:3340PubMed

19.

Ferlazzo G, Semino C, Spaggiari GM, Meta M, Mingari MC, Melioli G (2000) Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int Immunol 12:1741PubMed

20.

Fields RC, Shimizu K, Mule JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 95:9482CrossRefPubMed

21.

Fong L, Brockstedt D, Benike C, Wu L, Engleman EG (2001) Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166:4254PubMed

22.

Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245PubMed

23.

Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F (2002). Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell/leukemia cell hybrids and other antigen loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 51:299CrossRefPubMed

24.

Galea-Lauri J, Richardson AJ, Latchman DS, Katz DR (1996) Increased heat shock protein 90 (hsp90) expression leads to increased apoptosis in the monoblastoid cell line U937 following induction with TNF-alpha and cycloheximide—a possible role in immunopathology. J Immunol 157:4109PubMed

25.

Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5:1249PubMed

26.

Gilboa E, Nair SK, Boczkowski D (2000) Cancer immunotherapy with tumor RNA-transfected dendritic cells. Cancer Gene Ther 7:004CrossRef

27.

Girolomoni G, RicciardiCastagnoli P (1997) Dendritic cells hold promise for immunotherapy. Immunol Today 18:102CrossRefPubMed

28.

Gong JL, Chen DS, Kashiwaba M, Kufe D (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558PubMed

29.

Gong JL, Koido S, Chen DS, Tanaka Y, Huang L, Avigan D (2002) Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99:2512CrossRefPubMed

30.

Gong JL, Nikrui N, Chen DS, Koido S, Wu ZK, Tanaka Y, Cannistra S, Avigan D, Kufe D (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165:1705PubMed

31.

Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621CrossRefPubMed

32.

Gunzer M, Janich S, Varga G, Grabbe S (2001) Dendritic cells and tumor immunity. Semin Immunol 13:291CrossRefPubMed

33.

Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL (2000) Generation of tumor specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 60:3542PubMed

34.

Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzyl A, Bartsch G, Thurner M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777PubMed

35.

Homma S, Toda G, Gong JL, Kufe D, Ohno T (2001) Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 36:764PubMed

36.

Irvine AS, Trinder PKE, Laughton DL, Ketteringham H, McDermott RH, Reid SC, Haines AM, Amir A, Husain R, Doshi R, Young LS, Mountain A (2000) Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat Biotechnol 18:1273CrossRefPubMed

37.

Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A (1996) Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8(+) cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66:470PubMed

38.

Jenne L, Schuler G, Steinkasserer A (2001) Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 22:102CrossRefPubMed

39.

Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk JH (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243PubMed

40.

Karttunen J, Sanderson S, Shastri N (1992) Detection of rare antigen-presenting cells by the LacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci USA 89:6020PubMed

41.

Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337CrossRefPubMed

42.

Kovacsovicsbankowski M, Clark K, Benacerraf B, Rock K (1993) Efficient major histocompatibility complex class-I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A 90:4942PubMed

43.

Kurts C, Miller JFAP, Subramaniam RM, Carbone FR, Heath WR (1998) Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 188:409PubMed

44.

Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, Grabbe S (1999) Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 162:168PubMed

45.

Lappin MB, Weiss JM, Delattre V, Mai B, Dittmar H, Maier C, Manke K, Grabbe S, Martin S, Simon JC (1999) Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 98:181PubMed

46.

Li J, Holmes LM, Franek KJ, Burgin KE, Wagner TE, Wei Y (2001) Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 50:456CrossRefPubMed

47.

Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, Carbone FM, Heath WR (2001) Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 166:6099PubMed

48.

Ludewig B, McCoy K, Pericin M, Ochsenbein AF, Dumrese T, Odermatt B, Toes REM, Melief CJ, Hengartner H, Zinkernagel RM (2001) Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self- reactive CTL by dendritic cells. J Immunol 166:3678PubMed

49.

Lutz MB, Kukutsch N, Ogilvie ALJ, Rossner S, Koch F, Romani N, Schuler G (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223:77PubMed

50.

Lutz MB, Suri RM, Niimi M, Ogilvie ALJ, Kukutsch NA, Rossner S, Schuler G, Austyn JM (2000) Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 30:1813PubMed

51.

Luykx-de Bakker SA, de Gruijl TD, Scheper RJ, Wagstaff J, Pinedo HM (1999) Dendritic cells: a novel therapeutic modality. Ann Oncol 10:21CrossRef

52.

Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, Spagnoli G, Cerundolo V, Lindemann A (2000) Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86:385PubMed

53.

Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT (1995) Bone-marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1:1297PubMed

54.

Minev BR, Chavez FL, Dudouet BM, Mitchell MS (2000) Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1. Eur J Immunol 30:2115PubMed

55.

Moore MW, Carbone FR, Bevan MJ (1988) Introduction of soluble-protein into the class-I pathway of antigen processing and presentation. Cell 54:777PubMed

56.

Mule JJ (2000) Dendritic cells: at the clinical crossroads. J Clin Invest 105:707PubMed

57.

Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL (1999) Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39:54CrossRefPubMed

58.

Navabi H, Jasani B, Adams M, Evans AS, Mason M, Crosby T, Borysiewicz L (1997) Generation of in vitro autologous human cytotoxic T-cell response to E7 and HER-2/neu oncogene products using ex-vivo peptide loaded dendritic cells. Dendritic Cells in Fundamental and Clinical Immunology, vol 3. 417:583

59.

Nestle FO, Alijagic S, Gilliet M, Sun YS, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328PubMed

60.

Nestle FO (2000) Dendritic cell vaccination for cancer therapy. Oncogene 19:6673PubMed

61.

Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, Palucka KA (2000) Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 165:3797PubMed

62.

Paczesny S, Beranger S, Salzmann JL, Klatzmann D, Colombo BM (2000) Protection of mice against leukemia after vaccination with dendritic cells loaded with apoptotic leukemia cells. Cancer Gene Ther 7:1402

63.

Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317PubMed

64.

Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, Marincola FM (2000) Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 23:487PubMed

65.

Porgador A, Snyder D, Gilboa E (1996) Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918PubMed

66.

Porgador A, Yewdell JW, Deng YP, Bennink JR, Germain RN (1997) Localization, quantitation, and in situ detection of specific peptide MHC class I complexes using a monoclonal antibody. Immunity 6:715PubMed

67.

Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. Blood 93:2411PubMed

68.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Einhom JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321PubMed

69.

Sauter B, Albert M, Francisco L, Bhardwaj N (1999) Consequences of cell death: exposure to necrotic but not apoptotic cells induces the maturation of immunostimulatory dendritic cells. J Invest Dermatol 113:035

70.

Schreurs FWJ, Eggert AAO, Punt CJA, Figdor CG, Adema GJ (2000) Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy. Crit Rev Oncogenesis 11:1PubMed

71.

Schuler G, Steinman RM (1997) Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186:1183PubMed

72.

Shastri N, Gonzalez F (1993) Endogenous generation and presentation of the ovalbumin peptide/k(b) complex to T-cells. J Immunol 150:2724PubMed

73.

Shu SY, Cohen P (2001) Tumor-dendritic cell fusion technology and immunotherapy strategies. J Immunother 24:99CrossRef

74.

Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18:3894PubMed

75.

Strome SE, Voss S, Wilcox R, Wakefield TL, Tamada K, Flies D, Chapoval A, Lu J, Kasperbauer JL, Padley D, Vile R, Gastineau D, Wettstein P, Chen LP (2002) Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res 62:1884PubMed

76.

Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Schuler G (1999) Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669PubMed

77.

Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Engleman EG, Levy R (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517CrossRefPubMed

78.

Timmerman JM, Levy R (1999) Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50:507PubMed

79.

Trefzer U, Weingart G, Chen YW, Herberth G, Adrian K, Winter H, Audring H, Guo YJ, Sterry W, Walden P (2000) Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer 85:618PubMed

80.

Watts C (1997) Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 15:821PubMed

81.

Zitvogel L, Angevin E, Tursz T (2000) Dendritic cell-based immunotherapy of cancer. Ann Oncol 11:199CrossRefPubMed

Title: Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell–based cancer vaccination
Authors: Joanna Galea-Lauri
James W. Wells
David Darling
Phillip Harrison
Farzin Farzaneh
Publication date: 01-11-2004
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 11/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0542-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2004

Generation of human tumor-specific CTLs in HLA-A2.1–transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors

Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer

Autologous tumor vaccines processed to express α-gal epitopes: a practical approach to immunotherapy in cancer

Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?

Virosomes as new carrier system for cancer vaccines

Lower percentages of monocytes with CD80, CD86 and HLA-DR molecule expression in pediatric cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer